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OBJECTIVES To determine sarcolemmal Na1/H1 exchanger (NHE) activity and expression in human
ventricular myocardium.
BACKGROUND Although the sarcolemmal NHE has been implicated in various physiological and patho-
physiological phenomena in animal studies, its activity and expression in human myocardium
have not been studied.
METHODS Ventricular myocardium was obtained from unused donor hearts with acute myocardial
dysfunction (n 5 5) and recipient hearts with chronic end stage heart failure (n 5 11) through
a transplantation program. Intracellular pH (pHi) was monitored in enzymatically isolated
single ventricular myocytes by microepifluorescence. As the index of sarcolemmal NHE
activity, the rate of H1 efflux at a pHi of 6.90 (JH6.9) was determined after the induction of
intracellular acidosis in bicarbonate-free medium. Na1/H1 exchanger isoform 1 (NHE1)
expression in ventricular myocardium was determined by immunoblot analysis.
RESULTS Human ventricular myocytes exhibited readily detectable sarcolemmal NHE activity after the
induction of intracellular acidosis, and this activity was suppressed by the NHE1-selective
inhibitor HOE-642 (cariporide) at 1 mmol/L. Sarcolemmal NHE activity of myocytes was
significantly greater in recipient hearts (JH6.9 5 1.95 6 0.18 mmol/L/min) than it was in
unused donor hearts (JH6.9 5 1.06 6 0.15 mmol/L/min). In contrast, NHE1 protein was
expressed in similar abundance in ventricular myocardium from both recipient and unused
donor hearts.
CONCLUSIONS Sarcolemmal NHE activity of human ventricular myocytes arises from the NHE1 isoform
and is inhibited by HOE-642. Sarcolemmal NHE activity is significantly greater in recipient
hearts with chronic end-stage heart failure than it is in unused donor hearts, and this
difference is likely to arise from altered posttranslational regulation. (J Am Coll Cardiol 2000;
36:534–40) © 2000 by the American College of Cardiology
The sarcolemmal Na1/H1 exchanger (NHE) of cardiac
myocytes is believed to be the ubiquitous NHE isoform 1
(NHE1) of the multigene NHE family (1) and contributes
significantly to the integrated control of intracellular pH
(pHi) in this cell type (2). Na
1/H1 exchanger isoform 1
activity is regulated primarily by pHi through the interaction
of H1 with a “H1-sensor” site on the exchanger’s mem-
brane domain in a manner that results in exchanger activa-
tion in response to intracellular acidosis (3,4). Consistent
with this, the cardiac sarcolemmal NHE is relatively quies-
cent at physiological pHi, but its activity increases progres-
sively as pHi declines (2). Sarcolemmal NHE activity is also
modulated by a variety of neurohormonal stimuli such as
alpha1-adrenergic agonists (5,6), endothelin (7), thrombin
(8) and angiotensin II (9) through receptor-mediated mech-
anisms. These agents appear to increase sarcolemmal NHE
activity by increasing the pHi-sensitivity of the exchanger,
which is the mechanism known to underlie growth factor-
induced stimulation of NHE1 (3,4).
Recently, the sarcolemmal NHE has received attention as
a potential mediator of various physiological and pathophys-
iological phenomena in myocardium such as inotropic
responses to a variety of agonists (7,10–13) and muscle
stretch (14) and the induction of hypertrophy by mechanical
(15) and neurohormonal (16) stimuli. In addition, work
with the novel NHE1-selective inhibitors in our laboratory
(17–20) and by others (for recent reviews, see Avkiran [21]
and Karmazyn et al. [22]) has provided support for the
hypothesis that sarcolemmal NHE activity is an important
determinant of the severity of arrhythmias, contractile
dysfunction and tissue necrosis during myocardial ischemia
and reperfusion. Recent evidence suggests that NHE activ-
ity may also be involved in the induction of myocyte
apoptosis during ischemia and reperfusion (23,24) and
metabolic inhibition and recovery (25). These experimental
findings have instigated trials with NHE inhibitors in
clinical settings of myocardial ischemia and reperfusion,
such as the recent GUARDIAN (Guard during Ischemia
Against Necrosis) trial in patients with acute coronary
syndromes (26).
Although significant advances have been made, as de-
scribed above, in understanding of the regulation and roles
of the sarcolemmal NHE, these have been achieved exclu-
sively through the use of myocardial tissue and cells from a
variety of animal species. As a consequence, the applicability
to man of many of the findings is unconfirmed, and little is
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known regarding sarcolemmal NHE activity and expression
in human myocardium. We have used a microepifluores-
cence technique to determine, for the first time, sarcolem-
mal NHE activity in ventricular myocytes isolated from
explanted human hearts. In addition, we determined NHE
expression in ventricular myocardium of those hearts by
immunoblot analysis.
METHODS
Human ventricular myocytes. Ventricular myocardium
was obtained from explanted human hearts comprising 11
recipient hearts with chronic end-stage heart failure (eight
with ischemic heart disease and three with dilated cardio-
myopathy) and five donor hearts that were not used for
transplantation due to a low ejection fraction, as described
recently (27). Table 1 shows the characteristics of the
individuals from whom ventricular tissue was obtained over
a period of 15 months and the number and ventricular
origin of the cells from each preparation that were used in
the microepifluorescence studies. The mean age of patients
from whom recipient hearts were obtained was 49.3 6 3.2
years (n 5 11), which was significantly greater (p , 0.05,
unpaired t test) than that of the individuals from whom the
unused donor hearts originated (33.8 6 6.2 years, n 5 5).
Myocytes were isolated by enzymatic digestion of left or
right ventricular myocardium, as described in detail previ-
ously (28), and only rod shaped cells were used in the
microepifluorescence studies. Of the 112 myocytes listed in
Table 1, 87 (54 from recipient hearts and 33 from unused
donor hearts) were used for determination of sarcolemmal
NHE activity. The remainder were used for in situ calibra-
tion of the pH-sensitive fluorescent dye carboxy-
seminaphthorhodafluor-1 (C-SNARF-1), estimation of in-
trinsic buffering power (betai) and determination of the
NHE-inhibitory efficacy of HOE-642 (cariporide), a potent
NHE1-selective inhibitor (29), which we have shown to
inhibit sarcolemmal NHE activity in rat ventricular myo-
cytes (19) and which was tested in the GUARDIAN trial
(26).
Measurement of pHi and betai. The microepifluo-
rescence-based approach that was used to monitor pHi in
single cells has been described in detail previously (8) and
used in our earlier studies with rat ventricular myocytes
(5,6,8,9,19,30). In brief, cells loaded with C-SNARF-1
were placed on a glass coverslip in a 100 mL chamber and
fluorescence recordings made using a dual-emission pho-
tometer system (D104C; Photon Technology International
Inc.) during continuous superfusion (3.5 mL/min) with
bicarbonate-free Tyrode’s solution (34°C). Calibration was
with nigericin-containing solutions, and betai was estimated
during stepwise removal of extracellular NH4Cl, as de-
scribed (8). The calibration curve was obtained by nonlinear
least squares fit of normalized emission ratios; this gave
best-fit values for pK and a of 7.08 and 21.46, respectively,
which are similar to the values previously obtained in rat
ventricular myocytes (8).
Determination of sarcolemmal NHE activity. The rate of
acid efflux (JH) was used as the index of sarcolemmal NHE
activity, as in our previous work (5,6,8,9,19,30). After 5 to
10 min of superfusion with Tyrode’s solution, myocytes
were subjected to intracellular acidosis (in order to activate
the sarcolemmal NHE) by transient (5 min) exposure to 30
mmol/L NH4Cl and its subsequent washout (14 min).
Since pHi was lowered to #6.90 upon NH4Cl washout in
all cells that were subjected to this protocol, JH was
estimated at a pHi of 6.90 and termed JH6.9.
In experiments in which the NHE inhibitor HOE-642
was used, cells were subjected to two consecutive acid pulses
(as described above) separated by 10 min. During the
second acid pulse, HOE-642 (1 mmol/L) was included in
the superfusate during exposure to NH4Cl and the first
7 min of NH4Cl washout; HOE-642 was subsequently
removed from the Tyrode’s solution to assess the reversibil-
ity of drug action. With the same protocol, myocyte
contraction was monitored using a video edge-detection
system, as described before (31).
Determination of NHE and Na1/Ca21 exchanger ex-
pression. Myocardial expression of NHE1 was determined
at protein level by immunoblot analysis. In order to avoid
potential problems with differential recoveries of mem-
Abbreviations and Acronyms
betai 5 intrinsic buffering power
dpHi/dt 5 rate of recovery of pHi
JH 5 rate of H
1 efflux
JH6.9 5 rate of H
1 efflux at pHi 6.90
NCE 5 Na1/Ca21 exchanger
NHE 5 Na1/H1 exchanger
NHE1 5 Na1/H1 exchanger isoform 1
pHi 5 intracellular pH
Table 1. Origin of Human Ventricular Myocytes Used in
the Study
Heart No. Status
Age (yr)/
Gender
Cells
Studied
1 Recipient (IHD) 55/M 4 (RV)
2 Unused donor 22/F 12 (RV)
3 Unused donor 19/F 16 (RV)
4 Recipient (DCM) 20/M 10 (RV)
5 Recipient (DCM) 50/M 7 (LV)
6 Recipient (IHD) 48/M 11 (LV)
7 Unused donor 42/M 7 (LV)
8 Recipient (IHD) 49/M 4 (RV)
9 Recipient (IHD) 47/M 4 (RV)
10 Recipient (IHD) 55/M 5 (RV)
11 Unused donor 34/F 4 (LV)
12 Unused donor 52/F 4 (LV)
13 Recipient (IHD) 59/M 6 (RV)
14 Recipient (IHD) 56/F 4 (LV)
15 Recipient (IHD) 48/M 10 (RV)
16 Recipient (DCM) 55/M 4 (LV)
DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease; LV 5 left
ventricular; RV 5 right ventricular.
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branes from unused donor and recipient heart samples,
immunoblot analysis was conducted using unfractionated
tissue homogenates as described recently (32). Na1/Ca21
exchange (NCE) expression was also determined as a
positive control for the presence of sarcolemmal protein in
the samples. Ventricular tissue samples (approximately
0.2 g) obtained from regions without overt signs of fibrosis
or damage were rapidly thawed, weighed and homogenized
for 3 to 4 min in lysis buffer (sorbitol [5%], histidine
[pH 7.4; 25 mmol/L], Na2EDTA [50 mmol/L], KCl
[50 mmol/L], leupeptin [1 mg/mL], PMSF [0.5 mmol/L]
and benzamidine [1 mmol/L]). For NHE analysis, 0.5%
SDS and 0.1% beta-mercaptoethanol were added to 25 mL
of sample containing 100 mg of protein. After boiling for
5 min, 55 mL of lysis buffer and 5 mL of polyoxyethylene-
8-lauryl ether (Sigma, Poole, United Kingdom) were added
to the sample. After incubation at 37°C for 15 h, 50 mL of
33 SDS-sample buffer was added and the sample boiled for
10 min. For NCE analysis, SDS-sample buffer (31) was
added directly to an aliquot of tissue homogenate to obtain
a final protein concentration of 2 mg/mL and the sample
boiled for 10 min. After centrifugation, all samples (100 mg
protein) were subjected to electrophoresis using a 7.5%
SDS-polyacrylamide gel, and the separated proteins were
transferred to polyvinylidene difluoride membranes. Immu-
noblot analysis was performed using mouse monoclonal
antibody for NHE1 (1:500 dilution; #MAB3140, Chemi-
con International Inc., Harrow, United Kingdom) or NCE
(1:500 dilution; #C2C12, Cambridge BioScience, United
Kingdom) in conjunction with antimouse secondary anti-
body and enhanced chemiluminescence (Amersham Phar-
macia Biotech, Little Chalfont, United Kingdom).
Statistical analysis. For each heart, JH6.9 was determined
in up to 11 cells of either left or right ventricular origin
(Table 1), and an average value was obtained. Data for
unused donor and recipient groups are expressed as mean 6
SEM, with the n values representing the number of hearts
in each group. The unpaired t test was used to compare JH6.9
in recipient versus unused donor hearts, and p , 0.05 was
considered significant.
RESULTS
The rate of recovery of pHi (dpHi/dt) after an intracellular
acid load is determined not only by the JH but also by the
betai at the relevant pHi (33). Therefore, to obtain accurate
estimates of JH (as the index of sarcolemmal NHE activity),
it was necessary to determine betai in both populations of
myocytes. Our data revealed no difference in betai between
myocytes from recipient and unused donor hearts (Fig. 1).
Linear least squares regression analysis of all data points
gave the equation betai 5 233.7zpHi 1 260.1, which is very
similar to the equation that describes the relationship
between pHi and betai in rat ventricular myocytes (8). Basal
pHi values were not significantly different between myocytes
from recipient (7.31 6 0.02) and unused donor (7.29 6
0.03) hearts, and both groups of cells acidified to a similar
extent upon washout of NH4Cl, with minimal pHi values of
6.70 6 0.03 and 6.71 6 0.03, respectively. Myocytes from
recipient hearts exhibited faster recovery from acidosis, as
illustrated by the representative recordings shown in Figure
2A. Quantitative analysis of such data revealed that JH6.9
was significantly greater in myocytes from recipient hearts
than it was in cells from unused donor hearts (Fig. 2B).
Figure 1. The relationship between pHi and bi in human ventricular
myocytes obtained from unused donor hearts (open symbols) and recipient
hearts with end-stage heart failure (solid symbols). Linear least squares
regression analysis of all points gave the equation bi 5 233.7zpHi 1 260.1.
bi 5 intrinsic buffering power; pHi 5 intracellular pH.
Figure 2. (A) Representative single-cell pHi recordings during acid pulses
and (B) individual and mean JH6.9 values in ventricular myocytes obtained
from unused donor hearts (open symbols) and recipient hearts with
end-stage heart failure (solid symbols). In (B), n indicates the number of
hearts in each group. pHi 5 intracellular pH; JH6.9 5 rate of H
1 efflux at
pHi 6.90.
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To confirm that, under the conditions used, recovery of
pHi from acidosis in human ventricular myocytes occurred
predominantly by H1 efflux through the sarcolemmal
NHE, we exposed myocytes to intracellular acidosis in the
presence of HOE-642. As illustrated by the representative
recordings shown in Figure 3A, although there was rapid
recovery from acidosis under control conditions, such re-
covery was markedly suppressed in the presence of HOE-
642. The effect of HOE-642 was rapidly reversible, such
that when the inhibitor was removed from the superfusion
solution, pHi recovered from acidosis at a rate comparable
with that seen under control conditions (Fig. 3A). Figure
3B illustrates that the changes in pHi were paralleled by
changes in the amplitude of cell contraction. Thus, intra-
cellular alkalosis during NH4Cl exposure was associated
with an increase in contraction amplitude, while intracellu-
lar acidosis after NH4Cl washout was accompanied by a
reduction in contraction amplitude. Furthermore, HOE-
642 depressed the recovery of cell contraction after NH4Cl
washout, in parallel with its inhibitory effect on pHi recov-
ery from acidosis.
Immunoblot analysis of a random selection of ventricular
myocardium from unused donor and recipient hearts re-
vealed that the 110 kDa NHE1 protein was expressed in
similar abundance in all samples (Fig. 4A). Na/Ca21 ex-
changer expression was also readily detected in all samples as
two proteins of 120 and 70 kDa; these have been shown
previously to represent the intact NCE and a proteolytic
fragment, respectively, in human myocardium (32). In
contrast to NHE1, however, in three of the five recipient
hearts that were studied (heart numbers, 4, 10 and 13 in
Table 1), NCE protein was present in markedly greater
abundance (Fig. 4B). This difference in NCE abundance,
which is consistent with earlier reports (27,34), did not arise
from differential protein loading since Coomassie blue
staining (not shown) revealed comparable loading of sam-
ples.
DISCUSSION
Sarcolemmal NHE activity in human ventricular myo-
cytes. This study is the first to measure sarcolemmal NHE
activity in ventricular myocytes from human hearts. Our
data show that, after the induction of intracellular acidosis,
sarcolemmal NHE activity is readily detectable in human
myocytes, as has been shown to be the case in ventricular
myocytes from other species (2,8,11). Interestingly, sar-
colemmal NHE activity in ventricular myocytes from un-
used donor hearts appeared to be lower than that in
ventricular myocytes from normal rat hearts, measured using
the same equipment and methodology. Thus, mean JH6.9
was 1.06 6 0.15 mmol/L/min in five unused donor hearts
(33 cells) in this study, but 2.76 6 0.26 mmol/L/min in 37
rat cells randomly selected from those studied during an
overlapping period (5). This suggests the existence of
species-specific differences in the expression or regulation of
the sarcolemmal NHE.
Our finding that pHi recovery from acidosis in human
ventricular myocytes was inhibited by 1 mmol/L HOE-642
confirms that such recovery arose from H1 efflux through
the sarcolemmal NHE. Furthermore, this finding indicates
that the sarcolemmal NHE of human ventricular myocytes
Figure 3. Representative recordings of (A) pHi and (B) cell contraction in
human ventricular myocytes from recipient hearts with end-stage heart
failure during two consecutive acid pulses. The first acid pulses (open
symbols) were under control conditions whereas during the second acid
pulses (solid symbols) HOE-642 (1 mmol/L) was present during exposure
to NH4Cl and the first 7 min of NH4Cl washout, as indicated by the
horizontal bars. The baseline changes in (B) reflect changes in resting cell
length. pHi 5 intracellular pH.
Figure 4. Autoradiograms illustrating protein expression of (A) the
Na1/H1 exchanger (NHE1 isoform) and (B) the Na1/Ca21 exchanger in
ventricular samples from unused donor hearts and recipient hearts with
end-stage heart failure. Heart numbers relate to Table 1; in (B) the lane
between heart numbers 10 and 13 contained size markers.
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is indeed NHE1 since at 1 mmol/L HOE-642 is a selective
inhibitor of this isoform (29). This is consistent with work
by Fliegel and colleagues (35) who cloned NHE1 from a
human cardiac cDNA expression library. We also found
that changes in pHi, induced by NH4Cl pulses in the
absence or presence of HOE-642, produced parallel
changes in the amplitude of myocyte shortening. This is in
keeping with the established importance of pHi in regulat-
ing myocardial contractility (36) and consistent with the
recent observations of Ito et al. (37) on the effects of NH4Cl
pulses on cell shortening in rat ventricular myocytes.
Unused donor versus recipient myocardium. An interest-
ing and potentially important finding of this study is the
significantly greater sarcolemmal NHE activity of myocytes
in recipient hearts with chronic end-stage heart failure
relative to unused donor hearts with acute myocardial
dysfunction. That the abundance of NHE1 protein was
similar in ventricular tissue from unused donor hearts and
recipient hearts with end-stage heart failure suggests that
posttranslational mechanisms are likely to be responsible for
this difference in sarcolemmal NHE activity. Although
these mechanisms cannot be identified on the basis of the
present findings, it is interesting to note recent evidence that
the activities of protein kinase C (38) and Ca21/calmodulin
dependent kinase (39) are increased in human myocardium
with end-stage heart failure since both kinases have been
proposed as stimulatory regulators of sarcolemmal NHE
activity in rat ventricular myocytes (6–9,40).
In addition to a potential role for the kinase-mediated
signaling pathways outlined above, it may be argued that an
altered intracellular Na1 concentration, arising from an
increased NCE activity (see below), could also contribute to
the greater sarcolemmal NHE activity in recipient hearts
with end-stage heart failure. This is unlikely, however, since
recent work in sheep Purkinje fibers (41) has shown that
variation in the intracellular Na1 concentration is not a
physiologically important regulator of NHE activity in the
heart.
Ventricular myocytes from human myocardium with
end-stage heart failure exhibit varying degrees of hypertro-
phy (42). Therefore, the possibility that the observed dif-
ference in JH6.9 between recipient and unused donor hearts
may simply reflect a difference in the myocyte membrane
surface area to volume ratio needs to be considered. In this
context, a recent paper (43) has reported the first direct
measurements of membrane surface area (measured by cell
capacitance) and cell volume (measured by confocal micros-
copy) in control versus hypertrophied ventricular myocytes.
The findings of that study (43), which used rat ventricular
myocytes, have revealed that the membrane surface area to
volume ratio remains constant over a threefold increase in
cell volume, with no significant difference in this ratio
between control and hypertrophied cells. Therefore, the
difference in JH6.9 observed in this study between unused
donor versus recipient hearts is unlikely to be an artefact that
arises from myocyte hypertrophy in the latter; instead, it is
likely to reflect a true difference in sarcolemmal NHE
activity.
It is notable that, although sarcolemmal NHE activity of
myocytes was significantly greater in recipient hearts with
end-stage heart failure under conditions of intracellular
acidosis, basal pHi was not altered. This may indicate that,
at physiological values of pHi (.7.10), the sarcolemmal
NHE of myocytes was quiescent in both recipient and
unused donor hearts, as is the case in ventricular myocytes
from a variety of animal species (2,8,11). Maximum NHE
activity could not be determined in this study because it was
not possible to lower pHi below approximately 6.70 without
compromising myocyte viability.
Potential clinical relevance of findings. The NHE phe-
notype of healthy human myocardium is unknown and may
differ from that of the unused donor hearts used in this
study. However, if it is assumed that our novel data reflect
increased sarcolemmal NHE activity in end-stage heart
failure, then this change could have important (patho)phys-
iological consequences. In particular, the greater sarcolem-
mal NHE activity of failing myocardium may increase its
susceptibility to injury and dysfunction during ischemia and
reperfusion, in view of the proposed role of the exchanger in
this setting (see introduction). Indeed, experimental studies
have suggested that failing myocardium is more susceptible
to contractile dysfunction (44) and ventricular fibrillation
(45) during ischemia and reperfusion. In this context, it is
important to note that: (1) the mechanisms that underlie the
detrimental effects of increased NHE activity during myo-
cardial ischemia and reperfusion are thought to involve
Ca21 influx through NCE, operating in reverse mode (46),
and (2) expression of NCE protein is increased in failing
human myocardium (as shown in previous studies [27,34]
and confirmed here), and this is accompanied by greater
NCE activity (47). In the light of our findings, the question
of whether increased NHE activity contributes to the
development of heart failure also needs to be addressed,
particularly in view of the in vitro data that pharmacological
NHE inhibition attenuates the development of hypertrophy
in response to mechanical and neurohormonal stimuli in
neonatal (15) and adult (16) rat ventricular myocytes.
Our data may also have wider clinical relevance because
they represent the first direct evidence that human ventric-
ular myocytes express a functional NHE1 protein whose
activity is inhibited by HOE-642 in a readily reversible
manner. This NHE1-selective inhibitor was used in the
recent GUARDIAN trial, whose primary objective was to
determine whether NHE inhibition decreases the combined
incidence of mortality and myocardial infarction (both
Q-wave and non-Q-wave) in patients with acute coronary
syndromes (26). The preliminary results of this trial, as
presented at the 48th Scientific Sessions of the American
College of Cardiology (48), have shown no significant
reduction in the composite incidence of death and myocar-
dial infarction in response to drug treatment in the overall
study population. Nevertheless, with the highest dose of
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HOE-642 (120 mg intravenously three times a day), there
were significant reductions in the composite incidence of
death and myocardial infarction in patients undergoing
surgical revascularization and in the incidence of Q-wave
myocardial infarction in the other patient populations (48).
Although many factors may have contributed to these
findings, including the presence or absence of timely reper-
fusion (without which NHE inhibition would not be
expected to provide significant benefit [21]), it would be
important to determine whether an NHE-inhibitory con-
centration ($1 mmol/L) of HOE-642 was maintained in
the circulation during the period of risk in the various study
groups.
Concluding comments. Our present findings have shown
that ventricular myocytes from explanted human hearts
exhibit sarcolemmal NHE activity, which arises from the
NHE1 isoform and is inhibited by HOE-642 in a reversible
manner. Such activity is significantly greater in recipient
hearts with chronic end-stage heart failure than it is in
unused donor hearts with acute myocardial dysfunction.
This difference in sarcolemmal NHE activity occurs in the
absence of a difference in NHE1 protein expression in
recipient versus donor myocardium, which suggests the
involvement of posttranslational regulatory mechanisms.
Identification of the relevant molecular mechanisms and
determination of the functional significance of the observed
difference in sarcolemmal NHE activity require further
investigation.
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